Literature DB >> 3785524

Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984.

S Yoshida, D W Mulder, L T Kurland, C P Chu, H Okazaki.   

Abstract

The incidence, secular trend and survivorship of amyotrophic lateral sclerosis in the Rochester, Minn., population has been investigated over a 60-year period, 1925 through 1984. The crude average annual incidence rate was 2.0 per 100,000 population. The rate, age- and sex-adjusted to the US 1970 white population, was 2.4 per 100,000 population (3.0 for men and 2.0 for women), with a male to female ratio of 1.5:1. Incidence rates after 1955 showed a small but nonsignificant increase compared to those of the former 30-year period. Median age at onset was 67.5 years; the incidence rates increased significantly with advancing age, but without a peak. Median survivorship was 23.8 months, and younger patients had a better prognosis than patients with an advanced age at onset. No change in duration of survivorship was observed over the period studied. Two of the 44 patients (4.5%) had a family history of amyotrophic lateral sclerosis.

Entities:  

Mesh:

Year:  1986        PMID: 3785524     DOI: 10.1159/000110815

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  18 in total

1.  Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950.

Authors:  A M Chancellor; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

Review 2.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

3.  Affluence, age, and motor neuron disease.

Authors:  A M Chancellor; C P Warlow; V Carstairs; R A Elton; R J Swingler
Journal:  J Epidemiol Community Health       Date:  1992-04       Impact factor: 3.710

4.  The Scottish Motor Neuron Disease Register: a prospective study of adult onset motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-07       Impact factor: 10.154

Review 5.  Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity.

Authors:  Dmitry Kryndushkin; Frank Shewmaker
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

6.  Ecological correlates of motor neuron disease mortality: a hypothesis concerning an epidemiological association with radon gas and gamma exposure.

Authors:  S Neilson; I Robinson; F C Rose
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

Review 7.  British motor neuron disease twin study.

Authors:  A J Graham; A M Macdonald; C H Hawkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

8.  The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register.

Authors:  A M Chancellor; J M Slattery; H Fraser; R J Swingler; S M Holloway; C P Warlow
Journal:  J Neurol       Date:  1993-06       Impact factor: 4.849

Review 9.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

10.  Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis: the GENEVA study. Rationale, study design and demographic characteristics.

Authors:  Silke Schmidt; Kelli D Allen; Valerie T Loiacono; Barbara Norman; Catherine L Stanwyck; Kristina M Nord; Christina D Williams; Edward J Kasarskis; Freya Kamel; Valerie McGuire; Lorene M Nelson; Eugene Z Oddone
Journal:  Neuroepidemiology       Date:  2008-04-18       Impact factor: 3.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.